Recent 8-K filings for KRYS
Highest-materiality recent filing
Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients
- Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).
- Transduction rates ranged 29.4% to 42.1% across six patients; all biopsies positive for CFTR or viral marker.
-
Krystal Biotech shareholders approve all four proposals at 2026 annual meeting
Elected Krish S. Krishnan and Christopher Mason as Class III directors with ~89% and ~84% of votes cast.
-
Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates
VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.
-
Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111
Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.
-
Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030
Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.
-
Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).
-
Krystal Biotech director Kirti Ganorkar resigns effective Dec 31, 2025
Kirti Ganorkar resigned from Krystal Biotech Board on Dec 22, 2025 due to time constraints from promotion to Managing Director at Sun Pharma.
-
Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches
Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.
-
Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit
Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.
-
Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue
VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.
-
Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa
Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.
-
PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.
-
Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis
First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.
-
Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%
27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).
-
Krystal Biotech stockholders elect Class II directors, ratify KPMG, approve say-on-pay
Elected Daniel S. Janney, Dino A. Rossi, and E. Rand Sutherland as Class II directors for three-year terms.
-
Krystal Biotech presents preclinical data for KB111 (HHD) and KB112 (Darier) at SID 2025
KB111 targets ATP2C1 for Hailey-Hailey disease; KB112 targets ATP2A2 for Darier disease.
-
KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.
-
Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured
VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.
-
Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025
EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.
-
Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025
CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.
-
Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M
Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).
-
Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC
ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.
-
KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.
-
Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan
Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.
-
94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.
-
Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track
VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.
-
Class I directors Suma M. Krishnan, Julian S. Gangolli, and Catherine Mazzacco elected with 21.1M, 17.2M, and 20.4M votes for, respectively.
-
Krystal Biotech presents preclinical ocular gene therapy data at ARVO 2024
Subretinal and suprachoroidal injections achieved widespread mCherry expression across the retina in mice.
-
Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M
Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.75 · Most common event other_material